"Novel Biomarkers Can Be Used as Targets to Combat Cancer" by Harini Krishnan

Author(s)

Harini Krishnan

Date Approved

11-2014

Document Type

Dissertation

Degree Name

PhD in Cell and Molecular Biology

Department

Molecular Biology

College

Graduate School of Biomedical Sciences

First Advisor

Gary Goldberg, PhD

Committee Member 1

Ronald Ellis, PhD

Committee Member 2

Robert Nagele, PhD

Committee Member 3

Venkateswar Venkataraman, PhD

Committee Member 4

Maria Ramirez, PhD

Subject(s)

Neoplasms; Cadherins; src Tyrosine Kinases; Antineoplastic Agents; Biomarkers

Disciplines

Cancer Biology | Cell Biology | Laboratory and Basic Science Research | Medicine and Health Sciences | Molecular Biology | Neoplasms

Abstract

Cancer kills almost 8 million people per year worldwide. Therefore, about 13 people die from cancer every minute. Clearly, current cancer treatments are not completely effective. Moreover, many chemotherapeutic reagents are not very specific for cancer cells.

These agents attack rapidly dividing cells, including a wide array of normal cells, in addition to cancer cells, in the body. This lack of specificity can cause collateral damage and significant side effects in patients. More targeted therapies are needed to successfully combat cancer. Specific cancer biomarkers need to identified and characterized in order to develop better targeted anti-cancer drugs.

Tumor cells can be forced to assume a normal morphology by surrounding normal cells. This process is known as contact normalization. Tumor cells need to escape from contact normalization to migrate and metastasize.

Tumor cell motility is a critical step leading to cancer invasion and metastasis. Over 90% of cancer deaths result from metastasis, the spread of cancer from primary sites to distant parts of the body. We have identified unique receptors that promote tumor cell motility that is needed for cancer progression. These receptors can serve as novel cancer biomarkers and chemotherapeutic targets.

Share

COinS